Shares of NASDAQ APLS opened at $29.98 on Thursday ... the director now owns 100,000 shares of the company’s stock, valued at ...
But the meaning of this term in the glossary provided in Tai Nyori’s A Freedom Movement in the Twilight: Tribal Patriotism in ...
Stock Index Futures Gain With U.S. Presidential Election in Focus, Economic Data and Earnings on Tap
Economists foresee the October figure to be 55.3. U.S. Trade Balance data will be reported today as well ... Newmark Group (NMRK), National Health Investors (NHI), Apellis Pharma (APLS), Payoneer ...
Based on the one-year price targets offered by 18 analysts, the average target price for Apellis Pharmaceuticals Inc (NASDAQ:APLS) is $62.94 with a high estimate of $95 and a low estimate of $25.
Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a 7% quarter-over-quarter growth in commercial development for its product, with 84,500 vials shipped. The company achieved a significant ...
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Apellis Pharmaceuticals Third Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised ...
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $1.17 per share a year ago.
Commercial Vials Shipped: 84,500 vials of Syfovre in Q3 2024, a 7% increase from Q2 2024. Apellis Pharmaceuticals Inc (NASDAQ:APLS) reported a 7% quarter-over-quarter growth in commercial development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback